Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.
Halil YildizSarah BaillyEric Van Den NesteJean Cyr YombiPublished in: Therapeutics and clinical risk management (2021)
Relapsed or refractory HLH in adult patients is associated with poor outcome, and consolidation with HSCT may be required in some cases. Mortality related to HSCT is mainly due to active HLH disease before HSCT and post HSCT complications. New drugs, such as empalumab, ruxolitinib, and alemtuzumab are interesting since these agents may be used as bridges to HSCT with increases in the numbers of patients proceeding to HSCT and survival rate.
Keyphrases
- hematopoietic stem cell
- acute lymphoblastic leukemia
- end stage renal disease
- acute myeloid leukemia
- newly diagnosed
- multiple myeloma
- diffuse large b cell lymphoma
- ejection fraction
- chronic kidney disease
- hodgkin lymphoma
- risk factors
- peritoneal dialysis
- cardiovascular disease
- type diabetes
- patient reported outcomes
- free survival